echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Allogeneic CAR-T cell therapy treats leukemia and obtains FDA fast-track designation.

    Allogeneic CAR-T cell therapy treats leukemia and obtains FDA fast-track designation.

    • Last Update: 2020-09-05
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Precision Bioscience corporation announced that the U.S. Food and Drug Administration (FDA) has awarded its isometremic antigen-insignidant (CAR-T) cell therapy PBCAR0191 a fast-track designation for the treatment of advanced pregenicular B-cell acute lymphoblastic leukemia (B-ALL).
    Precision carefully selected high-quality T-cells from healthy feeds as starting materials and then modified T-cells in-body using its unique ARCUS genome editing technology.
    by inserting the CAR gene into the T-cell recipient (TCR) position, the process knocks out the CAR while knocking out the TCR, thus preventing the graft from being resistant to host disease.
    in vitro amplification and then returned to the patient for treatment.
    photo source: PBCAR0191 is currently in Phase 1/2a studies to assess its safety and tolerance in adult R/R B cell acute lymphoblastic leukemia (B-ALL) and R/R non-Hodgkin's lymphoma (NHL) patients.
    the NHL population, including patients with set cell lymphoma, PBCAR0191 was awarded the FDA's "Orphan Drug Title" for treatment of this subsype.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.